Drugs / Temsirolimus
last change Aug 2026 re-read 8 days ago

Temsirolimus

Small molecule targets FKBP1A, MTOR via inhibition

Developed for
renal cell carcinoma · cancer of unknown primary site · cancer · adult glioblastoma · gliosarcoma · mantle cell lymphoma · endometrial carcinoma · metastatic malignant neoplasm
+190 more · central nervous system neoplasm · giant cell glioblastoma · hepatocellular carcinoma · non-small cell lung carcinoma · plasma cell myeloma · prostate cancer · childhood malignant neoplasm · endometrial serous adenocarcinoma · Hodgkins lymphoma · lymphoma · melanoma · sarcoma · soft tissue sarcoma · anaplastic astrocytoma · anaplastic oligodendroglioma · breast cancer · diffuse large B-cell lymphoma · endometrial cancer · follicular lymphoma · glioblastoma · high grade malignant neoplasm · kidney cancer · lung carcinoid tumor · neoplasm · neuroblastoma · ovarian cancer · ovarian carcinoma · prostate adenocarcinoma · urinary bladder cancer · uterine corpus sarcoma · Waldenstrom macroglobulinemia · alveolar rhabdomyosarcoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · brain neoplasm · breast carcinoma · carcinoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · clear cell renal carcinoma · colorectal cancer · colorectal carcinoma · cutaneous melanoma · diffuse astrocytoma · endometrial adenosquamous carcinoma · endometrial clear cell adenocarcinoma · fallopian tube cancer · female reproductive system neoplasm · head and neck cancer · head and neck squamous cell carcinoma · hormone-resistant prostate carcinoma · male breast carcinoma · marginal zone lymphoma · metastatic melanoma · non-Hodgkin lymphoma · osteosarcoma · ovarian germ cell tumor · pancreatic adenocarcinoma · pancreatic endocrine carcinoma · PPoma · primary peritoneal carcinoma · prostate neoplasm · refractory malignant neoplasm · small cell lung carcinoma · squamous cell carcinoma · urothelial carcinoma · uterine carcinosarcoma · acute leukemia of ambiguous lineage · acute lymphoblastic leukemia · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute promyelocytic leukemia · adenocarcinoma · adenoma of pancreas · adult acute lymphoblastic leukemia · adult hepatocellular carcinoma · adult oligodendroglioma · alveolar soft part sarcoma · B-cell childhood acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia · B-cell non-Hodgkin lymphoma · botryoid rhabdomyosarcoma · brain cancer · brainstem neoplasm · breast neoplasm · Burkitt lymphoma · carcinoid tumor · carcinoma of pharynx · Castleman disease · castration-resistant prostate carcinoma · central nervous system disorder · cervical adenosquamous carcinoma · cervical cancer · cervical carcinoma · childhood acute lymphoblastic leukemia · childhood epithelioid sarcoma · childhood pleomorphic rhabdomyosarcoma · chronic myelomonocytic leukemia · colonic neoplasm · cutaneous neuroendocrine carcinoma · diffuse intrinsic pontine glioma · digestive system neuroendocrine tumor, grade 1/2 · endometrioid adenocarcinoma · Erdheim-Chester disease · Ewing sarcoma/peripheral primitive neuroectodermal tumor · fallopian tube carcinoma · female breast carcinoma · gastrointestinal stromal tumor · glioma · glucagonoma · hepatoblastoma · hereditary pheochromocytoma-paraganglioma · hypopharynx squamous cell carcinoma · large-cell immunoblastic lymphoma · larynx verrucous carcinoma · leukemia · leukemia, myeloid, accelerated-phase · lip and oral cavity carcinoma · liver and intrahepatic bile duct neoplasm · liver cancer · lung cancer · lymphangioleiomyomatosis · lymphoblastic lymphoma · major salivary gland carcinoma · male reproductive system neoplasm · malignant epithelial tumor of ovary · malignant pancreatic neoplasm · malignant peripheral nerve sheath tumor · malignant sex cord stromal tumor of ovary · MALT lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · medullary thyroid gland carcinoma · mesothelial neoplasm · metastatic squamous cell carcinoma · mixed glioma · mucosal melanoma · myelodysplastic syndrome · myelodysplastic syndrome with excess blasts · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · NF2-related schwannomatosis · nodal marginal zone B-cell lymphoma · oropharynx squamous cell carcinoma · ovarian carcinosarcoma · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian sarcoma · ovarian seromucinous carcinoma · ovarian serous surface papillary adenocarcinoma · pancreatic gastrinoma · pancreatic insulinoma · pancreatic somatostatinoma · paraganglioma · pediatric angiosarcoma · pediatric fibrosarcoma · pediatric liposarcoma · peripheral T-cell lymphoma, not otherwise specified · peritoneum cancer · pheochromocytoma · pilocytic astrocytoma · pineal body neoplasm · pineal gland astrocytoma · primary central nervous system lymphoma · prostate carcinoma · refractory anemia with excess blasts in transformation · relapsing-remitting multiple sclerosis · renal pelvis/ureter urothelial carcinoma · respiratory tract neoplasm · rhabdomyosarcoma · rhabdomyosarcoma with mixed embryonal and alveolar features · rheumatoid arthritis · salivary gland squamous cell carcinoma · spindle cell rhabdomyosarcoma · splenic marginal zone lymphoma · subependymal giant cell astrocytoma · synovial sarcoma · T-cell childhood acute lymphocytic leukemia · T-cell non-Hodgkin lymphoma · thyroid cancer · thyroid gland carcinoma · tongue carcinoma · triple-negative breast carcinoma · urethra cancer · uterine corpus cancer · verrucous carcinoma of oral cavity · desmoplastic small round cell tumor · Ewing sarcoma · limb ischemia · peripheral arterial disease
Investigated by
National Cancer Institute (NCI) · Wyeth is now a wholly owned subsidiary of Pfizer · Pfizer · M.D. Anderson Cancer Center · National Comprehensive Cancer Network · Washington University School of Medicine
+117 more · Memorial Sloan Kettering Cancer Center · NRG Oncology · AstraZeneca · Charite University, Berlin, Germany · Dana-Farber Cancer Institute · Genentech, Inc. · Puma Biotechnology, Inc. · AEterna Zentaris · AVEO Pharmaceuticals, Inc. · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Canadian Cancer Trials Group · Celgene Corporation · Central European Society for Anticancer Drug Research · City of Hope Medical Center · Duke University · Emory University · Hellenic Cooperative Oncology Group · Jonsson Comprehensive Cancer Center · Massachusetts General Hospital · Millennium Pharmaceuticals, Inc. · NATL COMP CA NETWORK · New Mexico Cancer Research Alliance · Radboud University Medical Center · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of California, San Francisco · University of Tennessee Cancer Institute · University of Wisconsin, Madison · AGO Study Group · Academic Medical Center - University of Amsterdam · Alliance for Clinical Trials in Oncology · American Society of Clinical Oncology · Andrew B Lassman, MD · Barrow Neurological Institute · Bristol-Myers Squibb · Cardiff University · Case Comprehensive Cancer Center · Centre Leon Berard · Children's Hospital of Orange County · Chinese University of Hong Kong · ClinAssess · Columbia University · Covance · Cristiana Sessa · Dartmouth-Hitchcock Medical Center · EMD Serono · European Organisation for Research and Treatment of Cancer - EORTC · Federation Francophone de Cancerologie Digestive · Fox Chase Cancer Center · French Innovative Leukemia Organisation · GIMEMA Foundation · Georg Hess, MD · Georgetown University · German Cancer Aid · German Cancer Research Center · GlaxoSmithKline · Goethe University · Gustave Roussy, Cancer Campus, Grand Paris · Gynecologic Oncology Group · Hannover Medical School · Hoffmann-La Roche · Institut Bergonié · Ivy Brain Tumor Center · Janssen Research & Development, LLC · Johann Wolfgang Goethe University Hospital · Johannes Gutenberg University Mainz · Loyola University · Ludwig-Maximilians - University of Munich · Mathias Witzens-Harig · McMaster University · MedSIR · Merck Sharp & Dohme LLC · Miller Children's & Women's Hospital Long Beach · Mundipharma K.K. · all 123 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (3) US (FDA) TORISEL — 2010-04-26 – 2012-05-30 fda.gov ↗
Approved EU (EMA) Torisel — 2007-11-19 europa.eu ↗
Approved US (FDA) TORISEL — 2007-05-30 fda.gov ↗

Trials 193 · started per year

today
US approved 2007
EU approved 2007
1
4
4
6
10
9
6
14
19
38
33
13
15
3
3
6
2
1
2
1
1
1
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT05773326 May 2023 → Feb 2025 glioblastoma Nader Sanai Terminated No outcome recorded
Phase 0 NCT02446431 Jul 2014 → Jul 2024 overdue cancer Miller Children's & Women's Hospital Long Beach Recruiting No outcome recorded
Phase 0 NCT01417065 Aug 2010 → Jun 2014 cancer of unknown primary site M.D. Anderson Cancer Center Completed No outcome recorded
Phase 169 trials
Phase 1 NCT03203525 Jun 2020 → Dec 2026 expected colorectal carcinoma, metastatic malignant neoplasm M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT02389309 Oct 2015 → Oct 2027 expected brain neoplasm, high grade malignant neoplasm M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT02420613 Oct 2015 → Mar 2025 diffuse intrinsic pontine glioma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT01614197 Jul 2015 → Dec 2019 childhood acute lymphoblastic leukemia, lymphoblastic lymphoma, peripheral T-cell lymphoma, not otherwise specified Therapeutic Advances in Childhood Leukemia Consortium Completed No outcome recorded
Phase 1 NCT02343718 Jun 2015 → Sep 2017 cancer, central nervous system disorder, lymphoma Canadian Cancer Trials Group Completed No outcome recorded
Phase 1 NCT02238496 Dec 2014 → Oct 2017 anaplastic astrocytoma, anaplastic oligodendroglioma, brain cancer, glioblastoma +1 Andrew B Lassman, MD Completed No outcome recorded
Phase 1 NCT01902160 Sep 2013 → May 2015 Hodgkins lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01596140 Dec 2012 → Jun 2020 cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT01552434 Oct 2012 → May 2026 Castleman disease, Erdheim-Chester disease, NF2-related schwannomatosis, breast carcinoma +11 M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1 NCT01712828 Oct 2012 → Jan 2013 — Celgene Corporation Completed No outcome recorded
Phase 1/231 trials · 3 missed
Phase 1/2 NCT03158389 May 2018 → Feb 2023 adult glioblastoma University Hospital Heidelberg Completed Mixed
Phase 1/2 NCT02423954 Apr 2015 → Nov 2017 cancer of unknown primary site, colorectal carcinoma, endometrial cancer, malignant pancreatic neoplasm +2 Western Regional Medical Center Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT01614301 May 2012 → May 2014 melanoma University of Regensburg Unknown No outcome recorded
Phase 1/2 NCT01389427 Nov 2011 → May 2015 mantle cell lymphoma The Lymphoma Academic Research Organisation Completed No outcome recorded
Phase 1/2 NCT01381692 Jul 2011 → Dec 2014 Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01335074 Apr 2011 → Dec 2013 hepatocellular carcinoma Philipps University Marburg Withdrawn No outcome recorded
Phase 1/2 NCT01206036 Jul 2010 → Sep 2014 prostate neoplasm Central European Society for Anticancer Drug Research Completed No outcome recorded
Phase 1/2 NCT01170052 May 2010 → Apr 2012 mantle cell lymphoma Charite University, Berlin, Germany Withdrawn No outcome recorded Stop: Enrollment
Phase 1/2 NCT01076543 Apr 2010 → Dec 2017 Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01111825 Apr 2010 → Jul 2016 breast cancer Puma Biotechnology, Inc. Completed No outcome recorded
Phase 276 trials · 4 met primary · 6 missed
Phase 2 NCT03297606 Mar 2018 → Dec 2026 expected non-Hodgkin lymphoma, plasma cell myeloma Canadian Cancer Trials Group Recruiting No outcome recorded
Phase 2 NCT02788201 Mar 2017 → Oct 2019 urinary bladder cancer, urothelial carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT02560012 Jan 2016 → Jul 2017 renal cell carcinoma The University of Texas Health Science Center, Houston Terminated No outcome recorded
Phase 2 NCT02142036 May 2014 → Aug 2018 metastatic malignant neoplasm Oslo University Hospital Completed Met primary
Phase 2 NCT01827267 Jul 2013 → Sep 2016 carcinoma Puma Biotechnology, Inc. Completed No outcome recorded
Phase 2 NCT01767194 Feb 2013 → Jun 2018 ganglioneuroblastoma, neuroblastoma National Cancer Institute (NCI) Completed Met primary
Phase 2 NCT01392183 Oct 2012 → Sep 2019 kidney cancer M.D. Anderson Cancer Center Completed Missed primary
Phase 2 NCT01687673 Oct 2012 → Apr 2016 hepatocellular carcinoma University of California, San Francisco Completed No outcome recorded
Phase 2 NCT01653067 Sep 2012 → Jun 2018 diffuse large B-cell lymphoma Mathias Witzens-Harig Unknown No outcome recorded
Phase 2 NCT01614795 Jun 2012 → Apr 2014 Ewing sarcoma/peripheral primitive neuroectodermal tumor, alveolar soft part sarcoma, childhood epithelioid sarcoma, gliosarcoma +7 National Cancer Institute (NCI) Completed No outcome recorded
Phase 38 trials · 2 met primary · 5 missed
Phase 3 NCT02567435 Jun 2016 → Jun 2023 overdue alveolar rhabdomyosarcoma, botryoid rhabdomyosarcoma, spindle cell rhabdomyosarcoma National Cancer Institute (NCI) Active not recruiting Missed primary
Phase 3 NCT01646021 Dec 2012 → Jun 2015 mantle cell lymphoma Janssen Research & Development, LLC Completed Met primary
Phase 3 NCT00980460 Sep 2009 → Jun 2020 hepatoblastoma National Cancer Institute (NCI) Completed Missed primary
Phase 3 NCT00631371 Apr 2008 → Apr 2012 renal cell carcinoma Pfizer Completed Missed primary
Phase 3 NCT00474786 Sep 2007 → Jan 2012 renal cell carcinoma Pfizer Completed Missed primary
Phase 3 NCT00117598 May 2005 → Aug 2007 lymphoma Pfizer Completed Met primary
Phase 3 NCT00083993 May 2004 → Oct 2006 breast cancer, metastatic malignant neoplasm Wyeth is now a wholly owned subsidiary of Pfizer Terminated Missed primary
Phase 3 NCT00065468 Jul 2003 → Jun 2006 renal cell carcinoma Pfizer Completed Mixed
Phase not applicable6 trials
— NCT04199026 Feb 2025 → Dec 2028 expected sarcoma M.D. Anderson Cancer Center Recruiting No outcome recorded
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT01326468 Dec 2011 → Dec 2016 head and neck cancer Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Withdrawn No outcome recorded Stop: Business
— NCT01369433 Jun 2010 → Jun 2015 cancer AVEO Pharmaceuticals, Inc. Terminated No outcome recorded
— NCT01404104 Sep 2008 → Aug 2014 renal cell carcinoma St. Joseph's Healthcare Hamilton Completed No outcome recorded
— NCT00235794 Jan 2004 → Sep 2007 prostate neoplasm Wyeth is now a wholly owned subsidiary of Pfizer Completed No outcome recorded
Comparator or background therapy11 trials
Phase 1 NCT00909831 Background Oct 2008 → May 2012 cancer of unknown primary site Abramson Cancer Center at Penn Medicine Completed No outcome recorded
Phase 1 NCT00659568 Background Mar 2008 → Feb 2010 breast cancer, cancer of unknown primary site, endometrial cancer, kidney cancer +2 London Health Sciences Centre Completed No outcome recorded
Phase 1 NCT00593060 Background Nov 2007 → Oct 2009 colorectal adenocarcinoma Jeffrey W. Clark, MD Completed No outcome recorded
Phase 2 NCT03942601 Comparator Oct 2019 → Apr 2021 peripheral arterial disease Mercator MedSystems, Inc. Terminated No outcome recorded
Phase 2 NCT02908035 Comparator Mar 2017 → Sep 2020 limb ischemia Mercator MedSystems, Inc. Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2014-12-12 Puma Biotechnology, Inc. Results Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Interim Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer pumabiotechnology.com ↗
2014-09-29 Puma Biotechnology, Inc. Results Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer pumabiotechnology.com ↗
The results of the study showed that the combination of PB272 and temsirolimus had acceptable tolerability.
2012-12-07 Puma Biotechnology, Inc. Results Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium Phase II Results Demonstrate Efficacy of PB272 in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer pumabiotechnology.com ↗
The results of the study presented showed that the combination of PB272 and temsirolimus had acceptable tolerability.
2011-12-09 Puma Biotechnology, Inc. Results Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium Phase II Results Demonstrate Efficacy of PB272 in Combination with Capecitabine and in Combination with Temsirolimus in HER2+ Metastatic Breast Cancer pumabiotechnology.com ↗
2011-06-02 AVEO Pharmaceuticals, Inc. Results Final Analysis from AVEO Pharmaceuticals’ Phase 2 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma Presented at ASCO aveooncology.com ↗
Additionally, Phase 1 data evaluating tivozanib in combination with the mTOR inhibitor temsirolimus (Torisel ® ) in patients with RCC demonstrated tolerability and tumor shrinkage.
2009-11-17 AVEO Pharmaceuticals, Inc. Results AVEO’s Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting aveooncology.com ↗
Preliminary results of this ongoing study show tumor shrinkage in 12 out of 16 patients evaluated, and two partial responses as assessed by RECIST criteria; the combination was well-tolerated with no dose limiting toxicities (DLT).

All press releases naming this drug 6 releases

DateIssuerRelease

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 207 sources stand behind the page.

FieldValueCited text
Known as Temsirolimus “Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression” NCT01251458 ↗
199

“Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017

“Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.” PMID 17538086 ↗ May 2007

“Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients” NCT00919035 ↗

“Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15” NCT01389427 ↗

“Tamoxifen, Temsirolimus, Teniposide” NCT02788201 ↗

“Sunitinib Temsirolimus Thioguanine” NCT02551718 ↗

“Temsirolimus” NCT01404104 ↗

“Temsirolimus” NCT02142036 ↗

NCT00877773 ↗

NCT00378703 ↗

Show 189 more sources

Known as CCI-779 “A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or...” NCT01182883 ↗
17

“The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly” NCT00065468 ↗

“Randomized, Double-Blind, Placebo-Controlled, Phase II Study Of Intravenous CCI-779 Administered Weekly To Patients With Androgen-Independent Prostate Cancer” NCT00012142 ↗

“Temsirolimus (CCI-779) has been widely investigated in different clinical settings and is presently registered for treatment of renal cell carcinomas.” NCT00827684 ↗

“Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse” NCT00926107 ↗

“Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily” NCT00062751 ↗

“CCI-779 (Temsirolimus; NSC-683864; IND-XXXX)” NCT00788580 ↗

“Temsirolimus = Toricel or CCI-779” NCT00996346 ↗

“CCI-779 (temsirolimus)” NCT00523432 ↗

“Temsirolimus (CCI-779)” NCT00494091 ↗

“Temsirolimus (CCI-779)” NCT00117598 ↗

Show 7 more sources

Known as CCI-779 Rapamycin Analog “CCI-779 Rapamycin Analog” NCT01076543 ↗
Known as NSC-683864 “Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas” NCT01016015 ↗
1

“CCI-779 (Temsirolimus; NSC-683864; IND-XXXX)” NCT00788580 ↗

Known as TEM “The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential.” PMID 34320785 ↗ Jul 2022
1

“Determine the maximum tolerated dose of hydroxychloroquine (HCQ) in combination with temsirolimus (TEM) in patients with metastatic refractory solid tumors.” NCT00909831 ↗

Known as Toricel “Temsirolimus = Toricel or CCI-779” NCT00996346 ↗
Known as Torisel “Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression” NCT01251458 ↗
8

“A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer” NCT00982631 ↗

“Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly.” NCT00474786 ↗

“Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15” NCT01389427 ↗

“This study uses one trialdrug: Temsirolimus (sometimes called Torisel ® ).” NCT01246817 ↗

“adventitial delivery of temsirolimus (Torisel)” NCT02908035 ↗

“Torisel (Temsirolimus)” NCT00770731 ↗

NCT00106353 ↗

NCT00919035 ↗

Known as Torisel (temsirolimus) “Torisel (temsirolimus)” NCT00563147 ↗
Action Inhibit “a specific inhibitor of the mammalian target of rapamycin kinase” PMID 17538086 ↗ May 2007
1

“FK506-binding protein 1A inhibitor” CHEMBL1201182 ↗

Modality Small molecule “Temsirolimus (CCI-779) is a soluble ester analogue of rapamycin (sirolimus)” NCT00703625 ↗
Route Intravenous “CCI-779 IV over 30 minutes” NCT00003712 ↗
Target FKBP1A “FK506-binding protein 1A inhibitor” CHEMBL1201182 ↗
Target MTOR “mammalian target of rapamycin kinase” PMID 17538086 ↗ May 2007